Denali Therapeutics Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 18/100
What the filing says
Denali Therapeutics agreed to sell its Priority Review Voucher (PRV)—awarded for its rare pediatric disease product AVLAYAH (tividenofusp alfa-eknm, approved March 24, 2026 for Hunter syndrome)—to an unnamed buyer for $195 million in cash. The agreement, effective June 12, 2026, requires HSR antitrust clearance and FDA notification of transfer. The voucher entitles its holder to priority FDA review of any future drug application. Denali retains no liabilities related to the voucher post-closing.
Why this rating
PRV sale ($195M) is ~18% of Denali's $1.1B market cap—material one-time cash influx, but PRV is intangible asset with no ongoing revenue stream. Reduces future optionality but generates immediate liquidity.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.